We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$4.11M
2
GILD icon
Gilead Sciences
GILD
+$2M
3
IBM icon
IBM
IBM
+$1.48M
4
CMG icon
Chipotle Mexican Grill
CMG
+$930K
5
EXPE icon
Expedia Group
EXPE
+$914K

Sector Composition

Rank Sector Weight
1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TTPH
426
CALL
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-2,250
Closed -$14K
TTPH
427
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-94
Closed -$9K
PTLA
428
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-59,600
Closed -$1K
PTLA
429
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-21,700
Closed -$4K
AKRX
430
DELISTED
Akorn Inc
AKRX
– –
-250
Closed -$6K
AKRX
431
PUT
DELISTED
Akorn Inc
AKRX
– –
-20,000
Closed -$49K
ACHN
432
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-30,000
Closed -$232K
ALDR
433
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-16,173
Closed -$396K
ALDR
434
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-5,000
Closed -$9K
SGYP
435
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-30,400
Closed -$1K
SGYP
436
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-27,765
Closed -$77K
KERX
437
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-115,000
Closed -$69K
FMI
438
CALL
DELISTED
Foundation Medicine, Inc.
FMI
– –
-10,600
Closed -$15K
CEMP
439
DELISTED
Cempra, Inc.
CEMP
– –
-9,400
Closed -$165K
CEMP
440
PUT
DELISTED
Cempra, Inc.
CEMP
– –
-1,000
Closed -$1K
KITE
441
CALL
DELISTED
Kite Pharma, Inc.
KITE
– –
-20,100
Closed -$6K
KITE
442
PUT
DELISTED
Kite Pharma, Inc.
KITE
– –
-5,000
Closed -$13K
DD
443
PUT
DELISTED
Du Pont De Nemours E I
DD
– –
-1,500
Closed -$17K
BHI
444
CALL
DELISTED
Baker Hughes
BHI
– –
-72,900
Closed -$51K
YHOO
445
CALL
DELISTED
Yahoo Inc
YHOO
– –
-39,200
Closed -$223K
MJN
446
DELISTED
Mead Johnson Nutrition Company
MJN
– –
-1,100
Closed -$93.1K
AEGR
447
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-16,345
Closed -$37.4K
RLYP
448
DELISTED
RELYPSA INC COM
RLYP
– –
-41,484
Closed -$728K
CVC
449
CALL
DELISTED
CABLEVISION SYS CP NY GRP CL-A
CVC
– –
-13,100
Closed -$53K
BXLT
450
DELISTED
BAXALTA INC COM STK (DE)
BXLT
– –
-19,673
Closed -$795K
15 16 17
18
19

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.